Literature DB >> 19357967

Intraoperative optical identification of pituitary adenomas.

M Sam Eljamel1, Graham Leese, Harry Moseley.   

Abstract

INTRODUCTION: The main goals of transsphenoidal pituitary surgery are total removal of pituitary adenomas (PAs) and preservation of normal pituitary functions. Achieving these goals is dependent upon the precise localisation of PAs during surgery, particularly secreting microadenomas. However, some microadenomas are invisible on preoperative imaging and during surgery, leading some surgeons to perform total hypophysectomy in many patients to achieve cure at the expense of panhypopituitrism. We have examined optical detection systems to identify PAs intraoperatively. This paper reports our preliminary findings.
METHODS: A prospective observational study design. TECHNIQUE: Patients were given 20 mg/kg body weight 5-aminolevulinic acid (ALA) mixed in 30 ml of orange juice, orally 3 h before surgery. Surgery was performed in the supine position, under image guidance, through the right nostril using Storz 0 degree endoscope assisted with microsurgery as required. The endoscope was attached to photodiagnostic filters (PD) allowing switching the light from white to blue at the flick of a foot pedal. After the dura of the floor of the sella was incised a laser probe was inserted into the pituitary gland to identify the ALA-induced protoporphyrin IX spectroscopy at 632 nm, using an optical biopsy system (OBS). Once the adenoma was identified by the OBS it was exposed and examined by the PD system to detect fluorescence. The PA was removed and its type was confirmed by histopathology and correlated to the OBS and PD system findings. PATIENTS: Thirty consecutive patients were studied: 14 were non-functioning macroadenomas (NFA), 12 were secreting PAs and 4 pituitary cysts. The secreting PAs were GH (2), ACTH (3), prolactin (2) and gonadotrophins (5). Six were microadenomas (3 ACTH, 1 GH, 2 prolactin) and 20 were macroadenomas, of which 12 were invading macroadenomas. Twenty-four of these were examined by the OBS and the PD systems and six were examined by the PD system only. The true positive (sensitivity) of the PD and OBS systems were 80.8% (21/26) and 95.5% (21/22) respectively. The true negative (specificity) of PD and OBS were 75% (3/4) and 100% (2/2) respectively. The false negative rate of PD was 19.2% (5/26) and for OBS was 4.5% (1/22), while the false positive rate for PD was 25% (1/4) and for OBS was 0.
CONCLUSION: Intraoperative optical identification of pituitary adenomas is a feasible and reliable way to localize pituitary adenomas during transsphenoidal surgery and it may lead to improved cure rate and preservation of normal pituitary functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357967     DOI: 10.1007/s11060-009-9820-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome.

Authors:  V Lefournier; B Gatta; M Martinie; A Vasdev; A Tabarin; P Bessou; J Berge; I Bachelot; O Chabre
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

2.  Neurologic complications of petrosal sinus sampling.

Authors:  D L Miller; J L Doppman; S B Peterman; L K Nieman; E H Oldfield; R Chang
Journal:  Radiology       Date:  1992-10       Impact factor: 11.105

Review 3.  Pituitary adenomas: results of 684 surgically treated patients and review of the literature.

Authors:  H H Oruçkaptan; O Senmevsim; O E Ozcan; T Ozgen
Journal:  Surg Neurol       Date:  2000-03

4.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  Petrosal sinus sampling for diagnosis of Cushing's disease: evidence of false negative results.

Authors:  J López; B Barceló; T Lucas; F Salame; C Alameda; M Boronat; L Salto; J Estrada
Journal:  Clin Endocrinol (Oxf)       Date:  1996-08       Impact factor: 3.478

6.  Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive?

Authors:  S Yokoyama; H Hirano; K Moroki; M Goto; S Imamura; J I Kuratsu
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

7.  Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.

Authors:  J Kreutzer; M L Vance; M B Lopes; E R Laws
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

8.  Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome.

Authors:  E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

9.  The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.

Authors:  D Jenkins; I O'Brien; A Johnson; R Shakespear; M C Sheppard; P M Stewart
Journal:  Clin Endocrinol (Oxf)       Date:  1995-11       Impact factor: 3.478

10.  Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas.

Authors:  M J Ebersold; L M Quast; E R Laws; B Scheithauer; R V Randall
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

View more
  16 in total

1.  In vivo reflectance confocal microscopy of shave biopsy wounds: feasibility of intraoperative mapping of cancer margins.

Authors:  A Scope; U Mahmood; D S Gareau; M Kenkre; J A Lieb; K S Nehal; M Rajadhyaksha
Journal:  Br J Dermatol       Date:  2010-12       Impact factor: 9.302

Review 2.  Optical technologies for intraoperative neurosurgical guidance.

Authors:  Pablo A Valdés; David W Roberts; Fa-Ke Lu; Alexandra Golby
Journal:  Neurosurg Focus       Date:  2016-03       Impact factor: 4.047

3.  Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery.

Authors:  Pablo A Valdés; Anthony Kim; Frederic Leblond; Olga M Conde; Brent T Harris; Keith D Paulsen; Brian C Wilson; David W Roberts
Journal:  J Biomed Opt       Date:  2011-11       Impact factor: 3.170

4.  5-ALA fluorescence-guided endoscopic surgery for mixed germ cell tumors.

Authors:  Junichi Takeda; Masahiro Nonaka; Yi Li; Yumiko Komori; Takamasa Kamei; Ryoichi Iwata; Tetsuo Hashiba; Kunikazu Yoshimura; Akio Asai
Journal:  J Neurooncol       Date:  2017-05-20       Impact factor: 4.130

5.  Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field.

Authors:  Stephanie W Chang; Daniel A Donoho; Gabriel Zada
Journal:  J Neurooncol       Date:  2018-12-06       Impact factor: 4.130

6.  Near-Infrared Optical Contrast of Skull Base Tumors During Endoscopic Endonasal Surgery.

Authors:  Jun W Jeon; Steve S Cho; Shayoni Nag; Love Buch; John Pierce; YouRong S Su; Nithin D Adappa; James N Palmer; Jason G Newman; Sunil Singhal; John Y K Lee
Journal:  Oper Neurosurg (Hagerstown)       Date:  2019-07-01       Impact factor: 2.703

7.  5-Aminolevulinic Acid and (18)F-FET-PET as Metabolic Imaging Tools for Surgery of a Recurrent Skull Base Meningioma.

Authors:  Jan Frederick Cornelius; Philipp Jörg Slotty; Gabriele Stoffels; Norbert Galldiks; Karl Josef Langen; Hans Jakob Steiger
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-01

Review 8.  Fluorescence guided surgery for pituitary adenomas.

Authors:  Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 9.  Fluorescence-guided surgery for brain tumors.

Authors:  Martin Hefti
Journal:  CNS Oncol       Date:  2013-01

Review 10.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.